860627P

C18 Dihydroceramide (d18:0/18:0)

Manufacturer: Sigma Aldrich

CAS Number: 2304-80-5

Synonym(S): N-stearoyl-D-erythro-sphinganine

Select a Size

Pack Size SKU Availability Price
5 MG 860627P-5-MG In Stock ₹ 12,557.00
25 MG 860627P-25-MG In Stock ₹ 48,625.90

860627P - 5 MG

₹ 12,557.00

In Stock

Quantity

1

Base Price: ₹ 12,557.00

GST (18%): ₹ 2,260.26

Total Price: ₹ 14,817.26

form

powder

packaging

pkg of 1 × 25 mg (860627P-25mg)pkg of 1 × 5 mg (860627P-5mg)

manufacturer/tradename

Avanti Polar Lipids 860627P

lipid type

sphingolipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC

InChI

1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1

InChI key

KZTJQXAANJHSCE-OIDHKYIRSA-N

Other Options

Image Product Name Manufacturer Price Range
C18 Dihydroceramide
-- ₹ 8,277.00 - ₹ 26,255.00
2304-80-5 | C18 DIHYDROCERAMIDE
-- ₹ 7,476.00 - ₹ 27,501.00

Related Products

Img

Sigma Aldrich

860518P

--

Img

Sigma Aldrich

860635P

--

Img

Sigma Aldrich

860624P

--

Img

Sigma Aldrich

860646P

--

Img

Sigma Aldrich

860658P

--

Img

Sigma Aldrich

860626P

--

Img

Sigma Aldrich

860629P

--

Img

Sigma Aldrich

860625P

--

Description

  • General description: C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1,[1] yields C18-dihydroceramide.[2]
  • Application: C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry.[3]
  • Biochem/physiol Actions: Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway.[4] vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients.[1] Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.[4]
  • Packaging: 5 mL Amber Glass Screw Cap Vial (860627P-25mg)